Clin Drug Invest. 2007;27(8):509-531. Antiretroviral drugs (ARVs) can be divided into four different classes according to their modes of action: nucleoside or nucleotide reverse transcriptase ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Nucleoside reverse transcriptase inhibitors appear to be neuroprotective, thus lowering the incidence of Alzheimer dementia. HealthDay News — Exposure to nucleoside reverse transcriptase inhibitors ...

LA JOLLA, CA — Calibr, the drug discovery and development division of Scripps Research, today announced Gilead Sciences, Inc. (Nasdaq: GILD) has exercised its option to exclusively license the ...

Children and adolescents in low- and middle-income countries living with HIV showed a reduced viral load after treatment with ...

Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors ...

The doravirine and islatravir pair could offer an alternative to INSTI-based treatment opt ...

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells No significant financial relationships to disclose. This is an ASCO ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...